ArticleCell biochemistry and biophysics2026
Integrated Transcriptomic Profiling and In Vitro Evaluation of Garcinia Mangostana Phytochemicals Against Cryptosporidium Parvum.
Article in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cryptosporidium parvum is a major cause of severe diarrheal disease, yet therapeutic options remain limited. This study integrated host-parasite transcriptomic profiling, GC-MS phytochemical profiling, computational screening, and in vitro experimental validation to evaluate anti-Cryptosporidium phytochemicals from Garcinia mangostana extract (GME). Host epithelial transcriptional responses (GSE2077) during C. parvum infection were analyzed to map infection-associated host reprogramming. A curated library of 30 identified phytochemicals was computationally docked against prioritized parasite-relevant targets: calcium-dependent protein kinase 1 (CDPK1), C. parvum 1-phosphatidylinositol 4-kinase [PI(4)K; cgd8_4500/UniProt Q5CVD3, AlphaFold model AF-Q5CVD3-F1], and cleavage and polyadenylation specificity factor 3 (CPSF3). The anti-Cryptosporidium efficacy of GME was subsequently evaluated in vitro by assessing C. parvum oocyst count and viability over 48 h. Transcriptomic analysis suggested a biphasic pattern of host reprogramming involving inflammatory signaling, sterol metabolism, Wnt signaling, and cell-cycle regulation. GC-MS analysis identified sterols and fatty acid derivatives, including stigmasterol, campesterol, and ethyl iso-allocholate. Molecular docking against the C. parvum PI(4)K model predicted campesterol (NP028) and ethyl iso-allocholate (NP029) as leading PI(4)K-oriented candidates, with mean affinities of - 7.97 ± 0.59 and - 7.72 ± 0.61 kcal/mol, respectively, while NP008 showed a predicted multi-target interaction profile, particularly against CPSF3. In vitro assays showed a significant, concentration- and time-dependent reduction in C. parvum oocyst viability, with an LC50 of 830 µg/mL after 48 h. Overall, the parasite-specific docking and oocysticidal data support GME phytochemicals as promising anti-Cryptosporidium candidates and generate testable hypotheses for CDPK1, PI(4)K, or CPSF3 involvement, while direct intracellular infection assays and recombinant enzyme inhibition studies are required to confirm target engagement.
Indexed as
Identifiers
42440248What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.